The DNA Behind Good Investing with Vincent Aita

Vincent Aita, founder and CIO of Cutter Capital Management and former molecular genetics researcher, shares his unique journey from academia to finance. He discusses how insights from the Human Genome Project shape his biotech investment strategies. Aita highlights the appeal of market-neutral strategies and the importance of adaptability in navigating healthcare investments post-COVID. The conversation delves into the transformative effects of genomic medicine and the complexities of drug approval processes in the U.S. and Europe.